(Q36762448)

16 August 2017

1 reference

title

Incidence and management of cutaneous toxicities associated with cetuximab (English)

1 reference

16 August 2017

1 reference

M Wasif Saif

1

1 reference

16 August 2017

Richard Kim

series ordinal

2

1 reference

16 August 2017

language of work or name

English

0 references

publication date

1 March 2007

1 reference

Expert Opinion on Drug Safety

16 August 2017

published in

1 reference

16 August 2017

volume

6

1 reference

16 August 2017

issue

2

1 reference

16 August 2017

page(s)

175-182

1 reference

Cetuximab: an epidermal growth factor receptor monoclonal antibody for the treatment of colorectal cancer

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.2.175

Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.2.175

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.2.175

Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.2.175

Cetuximab therapy and symptomatic hypomagnesemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.2.175

Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.2.175

Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.2.175

Follicular and epidermal alterations in patients treated with ZD1839 (Iressa), an inhibitor of the epidermal growth factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.2.175

Dermatologic Side Effects Associated with Gefitinib Therapy: Clinical Experience and Management

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.2.175

Management of acneiform rashes related to gefitinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.2.175

Epidermal growth factor receptor dimerization status determines skin toxicity to HER-kinase targeted therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.2.175

Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.2.175

Common side effects of anti-EGFR therapy: acneform rash

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.2.175

HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.2.175

Acneiform eruption induced by epidermal growth factor receptor inhibitors in patients with solid tumours.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.2.175

Practical management of patients with non-small-cell lung cancer treated with gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.2.175

Tetracyclines: nonantibiotic properties and their clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.2.175

The management of skin reactions in cancer patients receiving epidermal growth factor receptor targeted therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.2.175

Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.2.175

21 January 2018

Identifiers

DOI

10.1517/14740338.6.2.175

1 reference

16 August 2017

1 reference